Demographics of patients receiving TPOXX for treatment of mpox

Details

• Alternative Title:
  Demographics of patients receiving TPOXX for treatment of monkeypox
• Corporate Authors:
   National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of High-Consequence Pathogens and Pathology.
• Description:
  Updated January 25, 2023
  
  The data on this page will no longer be updated after 1/25/23.
  
  TPOXX (tecovirimat) use for treatment of mpox is authorized under Food and Drug Administration (FDA) regulations, and CDC holds an expanded access Investigational New Drug (EA-IND) protocol. The IND forms are required to be submitted to CDC. The demographics of patients prescribed TPOXX treatment are based on the patient intake forms CDC has received and abstracted. However, this number underestimates the number of patients who are receiving TPOXX treatment as healthcare providers can start treatment before submitting IND paperwork to CDC.
  
  
• Subjects:
  Antiviral Agents Drugs, Investigational Mpox (monkeypox) Poxviridae Infections/drug Therapy Smallpox/drug Therapy
• Document Type:
  Webpage
• Name as Subject:
  Tecovirimat ; Tecovirimat
• Place as Subject:
  United States
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:4c080daeac763709ec78ecc3e13fab5f58dffb7adbdf0338853a5f8ac1903442
• Download URL:
  https://stacks.cdc.gov/view/cdc/124138/cdc_124138_DS1.pdf
• File Type:
  [PDF - 1.63 MB ]